Preview

Кардиоваскулярная терапия и профилактика

Расширенный поиск

С-реактивный белок: современное состояние проблемы

Полный текст:

Аннотация

В обзоре изложены современные представления о С-реактивном белке (СРБ) как потенциальном факторе риска (ФР) прогрессирования атеросклероза. В настоящее время утверждение о том, что СРБ можно поставить в один ряд с такими классическими ФР, как артериальная гипертония, дислипидемия и курение, не является бесспорным. Однако признается его особая роль в качестве доказанного маркера воспаления, который рекомендуется использовать в клинической практике для уточнения степени риска пациента.

Об авторах

В. А. Жукова
Государственный научно-исследовательский центр профилактической медицины
Россия

аспирант отдела эпидемиологии неинфекционных заболеваний

Москва





С. А. Шальнова
Российский кардиологический научно-производственный комплекс
Россия

руководитель отдела планирования и координации научных исследований

Москва





В. А. Метельская
Государственный научно-исследовательский центр профилактической медицины
Россия

руководитель отдела изучения биохимических маркеров риска хронических неинфекционных заболеваний, Ученый секретарь

Москва





Список литературы

1. The World Health Report. Making a Difference. Geneva: World Health Organization 1999.

2. The World Health Report 2002: Reducing risks Promoting healthy life. Geneva: World Health Organization 2002.

3. American Heart Association. Statistical Fact Sheet – Population. International Disease Statistics. Dallas; Tex: American Heart Association 2003.

4. Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97(18): 1837-47.

5. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated levels of lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77: 1179-84.

6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 2001; 285: 2486-97.

7. De Backer G, Ambrosisni E, Borch-Johnsen et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24(17): 1601-10.

8. Ridker PM, Paynter NP, Rifai N, C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction. Circulation 2008; 118: 2243-51.

9. Khot UN, Khot MB, Baizer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290: 898-904.

10. Tillett WS, Francis T. Serologic reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930; 52: 561-71.

11. McCarty M. The occurrence during acute infections of a protein not normally present in the blood. IV. Crystallization of the C-reactive protein. J Exp Med 1947; 85: 491-8.

12. Kroop I, Shackman N. Levels of C-reactive protein as a measure of acute myocardial infarction. Proc Soc Exp Biol Med 1954; 86: 95-7.

13. Pearson TA, Mensah GA. Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.

14. Zacho J, Tybjaerg-Hansen A, Nordestgaard B G. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359: 1897-908.

15. Ross R. Atherosclerosis an Inflammatory disease. N Engl J Med 1999; 340(2): 115-26.

16. Yasojima K, Schwab C, McGeer EG, et al. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158: 1039-51.

17. Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested casecontrol study. Am J Epidemiol 1996; 144: 537-47.

18. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9. [Erratum, N Engl J Med 1997;337:356.]

19. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3.

20. Boekholdt SM, Hack CE, Sandhu MS, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis 2006; 187: 415-22.

21. Ridker PM, High-Sensitivity C-Reactive Protein as a Predictor of All-Cause Mortality: Implications for Research and Patient Care. Clinical Chemistry 2008; 54(2): 234-7.

22. Feskens EJM, Kromhout D. Fibrinogen and factor VII activity as risk factors for cardiovascular disease in an elderly cohort. Can J Cardiol 1997; 13(Suppl B): 282B.

23. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477-82.

24. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated metaanalyses. BMJ 2000; 321: 199-204.

25. Wang TJ, Nam BH, Wilson PW, et al. Association of C-reactive protein with carotid atherosclerosis in men and woman: the Framingham Heart Study. Arterioscl Tromb Vasc Biol 2002; 22: 1662-7.

26. Ridker PM, Charles H, Hennekens MD, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.

27. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65.

28. Koenig W, Sund M, Froelich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle aged men: results from MONICA (Monitoring trends and determinants in cardiovascular disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.

29. Albert MA, Glynn RJ Ridker PM, et al. Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score. Circulation 2003; 108: 161-5.

30. Ridker PM. C-reactive protein and risks of future myocardial infarction and thrombotic stroke. Eur Heart J 1998; 19: 1-3.

31. Ford ES. Body Mass Index, Diabetes, and C-Reactive Protein Among U.S. Adults. Diabetes Care 1999; 22: 1971-7.

32. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-34.

33. Han TS, Sattar N, Williams K, et al. Prospective Study of C-Reactive Protein in Relation to the Development of Diabetes and Metabolic Syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 2016-21.

34. Laaksonen DE, Niskanen L, Nyyssonen K, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004; 47: 1403-10.

35. Sesso HD, Burning GE, Rafai N, et al. C-reactive protein and the risk of development hypertension. JAMA 2003; 290: 2945-51.

36. Ridker PM, Cook NR, Lee IM, et al. A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. N Engl J Med 2005; 352.

37. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.

38. Morrow DA, Lemos JA. Benchmarks for the Assessment of Novel Cardiovascular Biomarkers. Circulation 2007; 115: 949-52.

39. Koenig W, Lowel H, Baumert J, et al. C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004; 109: 1349-53.

40. Cook NR, Buring JE, Ridker PM, et al. The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women. Ann Intern Med 2006; 145: 21-2.

41. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007; 297: 611-9.

42. Ridker P, Paynter N, Rifai N. C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction: The Reynolds Risk Score for Men. Circulation 2008; 118(22): 2243-51.

43. Zethelius B, Berglund L, SundstrΔm J, et al. Use of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular Causes. N Engl J Med 2008; 358: 2107-16.

44. Wang TJ, Gona P, Larson MG, et al. Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death. NEJM 2008; 358: 2107-16.


Для цитирования:


Жукова В.А., Шальнова С.А., Метельская В.А. С-реактивный белок: современное состояние проблемы. Кардиоваскулярная терапия и профилактика. 2011;10(1):90-95.

For citation:


Zhukova V.A., Shalnova S.A., Metelskaya V.A. C-reactive protein: modern state of the problem. Cardiovascular Therapy and Prevention. 2011;10(1):90-95. (In Russ.)

Просмотров: 235


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)